Conjugated Via A Specifically-identified Linking Group, Coupling Agent, Or Conjugation Agent Patents (Class 530/391.9)
-
Patent number: 8741291Abstract: The present invention relates to Multifunctional Antibody Conjugates, comprising an antibody or antigen binding portion thereof, comprising at least a fragment of a light chain constant kappa region (CL?) comprising K188 according to Kabat numbering; a linker comprising the formula X-Y-Z, wherein Z is a group is covalently connected to the antibody through the side chain of K188, Y is a linear or branched biologically compatible connecting chain, and X is a group covalently connected to at least one Effector Moiety. The invention further provides specific MAC compounds and compositions of the invention.Type: GrantFiled: November 28, 2011Date of Patent: June 3, 2014Assignee: Covx Technologies Ireland, LimitedInventors: Abhijit Suresh Bhat, Curt William Bradshaw, Olivier Alexandre Laurent, Alice Lee, Richard Ryan Preston, David Tumelty, Lauren Diane Wood, Wei Hong Yu
-
Patent number: 8742076Abstract: The present invention relates to antibody-drug conjugate compounds of Formula I: Ab-(L-D)p??I where one or more nemorubicin metabolite or analog drug moieties (D) are covalently attached by a linker (L) to an antibody (Ab) which binds to one or more tumor-associated antigens or cell-surface receptors. These compounds may be useful in methods of diagnosis or treatment of cancer, and other diseases and disorders.Type: GrantFiled: January 16, 2009Date of Patent: June 3, 2014Assignee: Genentech, Inc.Inventors: Robert L. Cohen, Edward HyungSuk Ha, Mark E. Reynolds
-
Publication number: 20140141025Abstract: The present disclosure provides conjugate structures (e.g., polypeptide conjugates) and hydrazinyl-indole compounds used to produce these conjugates. The disclosure also provides methods of production of such conjugates, as well as methods of using the same.Type: ApplicationFiled: March 11, 2013Publication date: May 22, 2014Applicant: REDWOOD BIOSCIENCE, INC.Inventors: Romas Alvydas Kudirka, Aaron Edward Albers, Robyn M. Barfield, David Rabuka
-
Publication number: 20140134193Abstract: The present invention is directed to novel cytotoxic spliceostatin analogs and derivatives, to antibody drug conjugates thereof, and to methods for using the same to treat medical conditions including cancer.Type: ApplicationFiled: October 31, 2013Publication date: May 15, 2014Applicant: PFIZER INC.Inventors: Chakrapani SUBRAMANYAM, Frank Erich KOEHN, Kenneth John DIRICO, Alessandra S. EUSTAQUIO, Michael Eric GREEN, Haiyin HE, Min HE, Christopher John O'DONNELL, Sujiet PUTHENVEETIL, Anokha RATNAYAKE, Jesse Alexander TESKE, Hui Yu YANG
-
Publication number: 20140127241Abstract: The invention relates to conjugates that bind to targets, methods of using conjugates that bind to targets and methods of treating undesirable or aberrant cell proliferation or hyperproliferative disorders, such as tumors, cancers, neoplasia and malignancies that express a target.Type: ApplicationFiled: October 30, 2013Publication date: May 8, 2014Inventors: CAROLA LEUSCHNER, HECTOR ALILA
-
Publication number: 20140127209Abstract: The invention relates inter alia to a bivalent, bispecific construct comprising an anti-IL-6 antibody, or derivative thereof, and an anti-IL-23 antibody, or derivative thereof and its use in therapy. The invention also relates to useful anti-IL-6 antibodies and anti-IL-23 antibodies.Type: ApplicationFiled: March 8, 2013Publication date: May 8, 2014Inventors: Kenneth GRABSTEIN, William BRADY, Gordon KING, Natalie Winblade NAIRN, Kurt David SHANEBECK, Paul Heffner SLAGLE, Kenneth Christopher THORNTON, Michael Peter VANBRUNT, Andrea WANG, Hengyu XU
-
Publication number: 20140127239Abstract: A compound which is either A: or B: and salts and solvates thereof, as well as their conjugates with a cell-binding agent.Type: ApplicationFiled: October 11, 2013Publication date: May 8, 2014Applicant: SPIROGEN SARLInventor: Philip Wilson HOWARD
-
Publication number: 20140127240Abstract: The present patent application relates to novel binder-drug conjugates (ADCs) of N,N-dialkylauristatins directed against the target epidermal growth factor receptor (EGFR, gene ID 1956), effective metabolites of these ADCs, methods for producing these ADCs, use of these ADCs for treatment and or prevention of diseases as well as the use of these ADCs to produce pharmaceutical drugs for treatment and/or prevention of diseases, in particular hyperproliferative and/or angiogenic diseases such as cancer, for example. Such treatments may be administered as monotherapy or in combination with other pharmaceutical drugs or other therapeutic measures.Type: ApplicationFiled: April 20, 2012Publication date: May 8, 2014Applicants: Bayer Pharma Aktiengesellschaft, Bayer Intellectual Property GmbHInventors: Hans-Georg Lerchen, Lars Linden, Sherif El Sheikh, Jörg Willuda, Charlotte C. Kopitz, Joachim Schuhmacher, Simone Greven, Christoph Mahlert, Beatrix Stelte-Ludwig, Sven Golfier, Rudolf Beier, Iring Heisler, Axel Harrenga, Karl-Heinz Thierauch, Sandra Bruder, Heike Petrul, Hannah Jörißen, Sandra Brokowski
-
Publication number: 20140105922Abstract: The present invention provides variant target binding agents and methods relating to the use of such binding agents for the prophylaxis or treatment of cancers and immunological disorders. The variant target binding agent is conjugated to a therapeutic agent that exerts a cytotoxic, cytostatic, or immunomodulatory effect on target cells.Type: ApplicationFiled: March 14, 2013Publication date: April 17, 2014Applicant: SEATTLE GENETICS, INC.Inventor: SEATTLE GENETICS, INC.
-
Publication number: 20140105915Abstract: The present invention concerns antigen binding proteins and fragments thereof which specifically bind B Cell Maturation Antigen (BCMA), particularly human BCMA (hBCMA) and which inhibit the binding of BAFF and APRIL to the BCMA receptor. Further disclosed are pharmaceutical compositions, screening and medical treatment methods.Type: ApplicationFiled: May 24, 2012Publication date: April 17, 2014Applicant: Glaxo Group LimitedInventors: Paul Algate, Stephanie Jane Clegg, Jennifer L. Craigen, Paul Andrew Hamblin, Alan Peter Lewis, Patrick Mayes, Radha Shah Parmar, Trevor Anthony Kenneth Wattam
-
Publication number: 20140093522Abstract: The invention relates to a Prodrug activation method, for therapeutics, wherein use is made of abiotic reactive chemical groups that exhibit bio-orthogonal reactivity towards each other. The invention also relates to a Prodrug kit comprising at least one Prodrug and at least one Activator, wherein the Prodrug comprises a Drug and a first Bio-orthogonal Reactive Group (the Trigger), and wherein the Activator comprises a second Bio-orthogonal Reactive Group. The invention also relates to targeted therapeutics used in the above-mentioned method and kit. The invention particularly pertains to antibody-drug conjugates and to bi- and trispecific antibody derivatives.Type: ApplicationFiled: May 16, 2012Publication date: April 3, 2014Applicant: KONINKLIJKE PHILIPS N.V.Inventors: Marc Stefan Robillard, Hendricus Marie Janssen, Wolter Ten Hoeve, Ronny Mathieu Versteegen, Raffaella Rossin
-
Publication number: 20140093523Abstract: The invention relates to conjugates of anti-integrin specific antibodies with cytotoxic compounds, the synthesis, selection, and use of such conjugates for use in cancer therapy or other diseases mediated by cell proliferation, cell migration, or inflammation and which pathology involves angiogenesis or neovascularization of new tissue. In addition the invention relates to combination therapy of such diseases wherein the treatment comprises use of said conjugates in combination with one or more other treatment modalities including but not limited to: chemotherapy, surgery or radiation therapy. The preferred conjugates contain maytansinoid compounds linked to the antibody by a disulfide linkage, and preferred chemotherapeutic agents are doxorubicin, a taxane, a camptothecin, a podophyllotoxin, a nucleoside analog, or a pyrimidine analog.Type: ApplicationFiled: December 4, 2013Publication date: April 3, 2014Applicants: Immunogen, Inc., Janssen Biotech, Inc.Inventors: Qiming Chen, Mohit Trikha, Robert J. Lutz, Rita M. Steeves, Godfrey Amphlett
-
Publication number: 20140088089Abstract: The invention relates to novel benzodiazepine derivatives with antiproliferative activity and more specifically to novel benzodiazepine compounds, such as those in formulas (V)-(VII). The invention also provides conjugates of the benzodiazepine compounds linked to a cell-binding agent. The invention further provides compositions and methods useful for inhibiting abnormal cell growth or treating a proliferative disorder in a mammal using the compounds or conjugates of the invention. The present invention is further directed to methods of preparing a conjugate of a cell-binding agent and a cytotoxic compound. The methods comprise the use of an imine reactive compound to enable efficient conjugations of cytotoxic compounds with cell binding agents.Type: ApplicationFiled: February 15, 2012Publication date: March 27, 2014Applicant: ImmunoGen, INC.Inventor: Ravi V.J. Chari
-
Patent number: 8680315Abstract: The present invention provides methods and compositions that permit controlled and prolonged drug release in vivo. The compounds are either prodrugs with tunable rates of release, or conjugates of the drug with macromolecules which exhibit tunable controlled rates of release.Type: GrantFiled: June 26, 2009Date of Patent: March 25, 2014Assignee: Prolynx, LLCInventors: Daniel V. Santi, Gary W. Ashley
-
Publication number: 20140081005Abstract: Disclosed are anti-5T4 antibody drug conjugates and methods for preparing and using the same.Type: ApplicationFiled: October 14, 2013Publication date: March 20, 2014Applicant: WYETH LLCInventors: Hans-Peter Gerber, John Francis DiJoseph, Kiran Manohar Khandke, Kimberly Ann Marquette, Puja Sapra, Lioudmila Gennadievna Tchistiakova
-
Publication number: 20140079722Abstract: Antibodies targeting the dysadherin subunit of the human Na,K-ATPase signaling complex that are covalently linked via a stable linker to steroid drugs that bind the alpha subunit of that complex are useful in the treatment of cancer.Type: ApplicationFiled: March 9, 2012Publication date: March 20, 2014Applicant: CENTROSE, LLCInventor: James R. Prudent
-
Publication number: 20140072586Abstract: Antibody drug conjugates (ADC's) that bind to 158P1D7 protein and variants thereof are described herein. 158P1D7 exhibits tissue specific expression in normal adult tissue, and is aberrantly expressed in glioblastoma, lung cancer, bladder cancer, and breast cancer. Consequently, the ADC's of the invention provide a therapeutic composition for the treatment of cancer.Type: ApplicationFiled: August 23, 2013Publication date: March 13, 2014Applicants: SEATTLE GENETICS, INC., AGENSYS, INC.Inventors: Robert Kendall MORRISON, Zili AN, Karen Jane Meyrick MORRISON, Josh SNYDER, Xiao-Chi JIA
-
Publication number: 20140065171Abstract: The present invention provides methods of site-specific labeling of antibodies, using proteins having 4?-phosphopantetheinyl transferase activity that catalyze post-translational modification of peptide sequences (“peptide tags”) incorporated into one or more specific sites of an antibody of interest. Enzymatic labeling enables quantitative and irreversible covalent modification of a specific serine residue within the peptide tags incorporated into the antibody, and thus creates desirable antibody conjugates.Type: ApplicationFiled: May 31, 2013Publication date: March 6, 2014Inventors: Bernhard Hubert GEIERSTANGER, Jan GRUNEWALD, Badry BURSULAYA
-
Publication number: 20140058067Abstract: The present invention relates to therapeutic conjugates with improved ability to target various diseased cells containing a targeting moiety (such as an antibody or antibody fragment), a linker and a therapeutic moiety, and further relates to processes for making and using the conjugates.Type: ApplicationFiled: October 8, 2013Publication date: February 27, 2014Applicant: IMMUNOMEDICS, INC.Inventors: Serengulam V. Govindan, Sung-Ju Moon, David M. Goldenberg
-
Publication number: 20140056926Abstract: The present invention relates to a complex in which an anti-cotinine antibody is bound to a conjugate of a binding material and cotinine, and a use of the complex. The complex according to the present invention may be used as an analysis tool in an in vitro biological assay method, and may retain the specific reactivity and the biological function of the binding material, and the capabilities of inducing complement-mediated cell cytotoxicity (CDC) and antibody-dependent cell cytotoxicity (ADCC) and a prolonged in vivo half-life, which are intrinsic characteristics of an antibody.Type: ApplicationFiled: April 16, 2012Publication date: February 27, 2014Applicant: SNU R&DB FOUNDATIONInventors: Junho Chung, Sunyoung Park, Do Been Hwang, Hwa Kyoung Lee
-
Publication number: 20140050746Abstract: Drug Linker compounds and Drug Linker Ligand conjugates are provided that have auristatins linked via the C-terminus. The conjugates show efficacy without the need for a self-immolative group to release the drug.Type: ApplicationFiled: October 23, 2013Publication date: February 20, 2014Applicant: Seattle Genetics, Inc.Inventors: Peter Senter, Svetlana Doronina, Timothy Bovee
-
Publication number: 20140051836Abstract: Provided herein are modified Fc proteins comprising non-natural amino acid residues at site-specific positions, conjugates of the modified Fc proteins for therapy or diagnosis, compositions comprising the modified Fc proteins and conjugates thereof, methods of their production and methods of their use. The modified Fc proteins and conjugates are useful for methods of treatment and prevention, methods of detection and methods of diagnosis.Type: ApplicationFiled: June 26, 2013Publication date: February 20, 2014Inventors: Christopher D. Thanos, Leslie McEvoy, Gang Yin, Kalyani Penta, Ramesh Baliga, Sunil Bajad, Sonia Pollitt, Chris Murray, Alex Steiner, Avinash Gill
-
Publication number: 20140045242Abstract: The present invention concerns methods and compositions for forming anti-cancer vaccine complexes. In preferred embodiments, the anti-cancer vaccine complex comprises an antibody moiety that binds to dendritic cells, such as an anti-CD74 antibody or antigen-binding fragment thereof, attached to an AD (anchoring domain) moiety and a xenoantigen, such as CD20, attached to a DDD (dimerization and docking domain) moiety, wherein two copies of the DDD moiety form a dimer that binds to the AD moiety, resulting in the formation of the vaccine complex. The anti-cancer vaccine complex is capable of inducing an immune response against xenoantigen expressing cancer cells, such as CD138negCD20+ MM stem cells, and inducing apoptosis of and inhibiting the growth of or eliminating the cancer cells.Type: ApplicationFiled: September 16, 2013Publication date: February 13, 2014Applicant: IBC PHARMACEUTICALS, INC.Inventors: Chien-Hsing Chang, David M. Goldenberg
-
Publication number: 20140046030Abstract: Provided herein are antibodies comprising non-natural amino acid residues at site-specific positions, compositions comprising the antibodies, methods of their production and methods of their use. The antibodies are useful for methods of treatment and prevention, methods of detection and methods of diagnosis.Type: ApplicationFiled: June 7, 2013Publication date: February 13, 2014Applicant: Sutro Biopharma, Inc.Inventors: Christopher D. Thanos, Leslie McEvoy, Gang Yin, Kalyani Penta, Ramesh Baliga, Sunil Bajad, Sonia Pollitt, Chris Murray, Alex Steiner, Avinash Gill
-
Publication number: 20140039158Abstract: Methods of preparing polymer target conjugates which are substantially free of polymer attachment on the N-terminal of the targets are provided. Also provided are compositions comprising a plurality of polymer-polypeptide conjugates, said polymer-polypeptide conjugate comprising a polypeptide covalently attached to at least one polymer through an epsilon amino group of a Lysine or a Histidine found on the polypeptide and said conjugates containing less than 5% of the polymer-polypeptide conjugates having a polymer attached to the N-terminal of the polypeptide; and polymer target conjugates comprising a target moiety selected from the group consisting of polypeptides, proteins and the like having at least one polymer attached thereto at a site which is not the N-terminal of the target.Type: ApplicationFiled: July 25, 2013Publication date: February 6, 2014Applicant: Belrose Pharma, Inc.Inventor: Hong Zhao
-
Publication number: 20140030273Abstract: Isolated human monoclonal antibodies which bind to human CD74 and related antibody-drug conjugates are disclosed. Pharmaceutical compositions comprising the antibodies or antibody-drug conjugates, and therapeutic and diagnostic methods for using the antibodies and/or antibody-drug conjugates, are also disclosed.Type: ApplicationFiled: February 1, 2012Publication date: January 30, 2014Applicant: GENMAB A/SInventors: Sandra Verploegen, Marije Overdijk, Riemke Van Dijkhuizen, Willem Karel Bleeker, Patrick Van Berkel, Paul Parren, Steen Lisby
-
Publication number: 20140030280Abstract: The invention provides anti-CD79b antibodies and immunoconjugates and methods of using the same.Type: ApplicationFiled: July 8, 2013Publication date: January 30, 2014Applicant: Genentech, Inc.Inventors: Paul Polakis, Andrew Polson, Susan Diane Spencer, Shang-Fan Yu
-
Publication number: 20140030281Abstract: The invention provides anti-CD22 antibodies and immunoconjugates and methods of using the same.Type: ApplicationFiled: July 8, 2013Publication date: January 30, 2014Applicant: Genentech, Inc.Inventors: Paul Polakis, Andrew Polson, Susan Diane Spencer, Shang-Fan Yu, Bing Zheng
-
Publication number: 20140030279Abstract: The invention provides anti-CD22 antibodies and immunoconjugates and methods of using the same.Type: ApplicationFiled: July 8, 2013Publication date: January 30, 2014Applicants: Spirogen Sarl, Genentech, Inc.Inventors: Paul Polakis, Andrew Polson, Susan Diane Spencer, Shang-Fan Yu, John A. Flygare, Janet L. Gunzner-Toste, Thomas Harden Pillow, Philip Wilson Howard, Luke Masterson
-
Publication number: 20140030282Abstract: The invention provides anti-CD79b antibodies and immunoconjugates and methods of using the same.Type: ApplicationFiled: July 8, 2013Publication date: January 30, 2014Applicant: Genentech, Inc.Inventors: Paul Polakis, Andrew Polson, Susan Diane Spencer, Shang-Fan Yu, Bing Zheng
-
Publication number: 20140023666Abstract: The present invention relates to new auristatin compounds and prodrugs thereof, compositions comprising them and uses thereof.Type: ApplicationFiled: March 29, 2012Publication date: January 23, 2014Inventors: George R. Pettit, Fiona Hogan, Steven Toms
-
Publication number: 20140010810Abstract: This invention relates generally to the generation of antibodies, e.g., monoclonal antibodies including fully human monoclonal antibodies, that recognize Jagged 1 and/or Jagged 2, to antibodies, e.g., monoclonal antibodies including fully human antibodies that recognize Jagged 1 and/or Jagged 2, and nucleic acid molecules that encode antibodies, e.g., nucleic acid molecules that encode monoclonal antibodies including fully human cross-reactive antibodies that recognize both Jagged 1 and Jagged 2, and to methods of making the anti-Jagged antibodies and methods of using the anti-Jagged antibodies as therapeutics, prophylactics, and diagnostics. The invention also relates generally to activatable antibodies that include a masking moiety (MM), a cleavable moiety (CM), and an antibody (AB) that specifically bind to Jagged 1 and Jagged 2, and to methods of making and using these activatable anti-Jagged antibodies in a variety of therapeutic, diagnostic and prophylactic indications.Type: ApplicationFiled: June 21, 2013Publication date: January 9, 2014Inventors: James William West, Jason Gary Sagert, Paul H. Bessette, Henry Bernard Lowman, Nancy E. Stagliano, Olga Vasiljeva, Elizabeth-Edna Mary Menendez
-
Patent number: 8624003Abstract: This invention describes a method of conjugating a cell binding agent such as an antibody with an effector group (e.g., a cytotoxic agent) or a reporter group (e.g., a radionuclide), whereby the reporter or effector group is first reacted with a bifunctional linker and the mixture is then used without purification for the conjugation reaction with the cell binding agent. The method described in this invention is advantageous for preparation of stably-linked conjugates of cell binding agents, such as antibodies with effector or reporter groups. This conjugation method provides in high yields conjugates of high purity and homogeneity that are without inter-chain cross-linking and inactivated linker residues.Type: GrantFiled: June 3, 2010Date of Patent: January 7, 2014Assignee: ImmunoGen, Inc.Inventors: Brenda A. Kellogg, Rajeeva Singh, Ravi V. J. Chari
-
Patent number: 8613930Abstract: Charged or pro-charged cross-linking moieties and conjugates of cell binding agents and drugs comprising the charged or pro-charged cross-linking moieties and method of making the same.Type: GrantFiled: July 5, 2012Date of Patent: December 24, 2013Assignee: ImmunoGen, Inc.Inventors: Ravi V. J. Chari, Robert Yongxin Zhao, Yelena Kovtun, Rajeeva Singh, Wayne Charles Widdison
-
Publication number: 20130336885Abstract: The invention provides anti-LgR5 antibodies and immunoconjugates and methods of using the same.Type: ApplicationFiled: March 29, 2013Publication date: December 19, 2013Applicant: GENENTECH INC.Inventors: Jo-Anne Hongo, Weiguang Mao, Paul Polakis, Andrew Polson, Rajesh Vij, Yan Wu, Wei-Ching Liang
-
Patent number: 8609105Abstract: Drug Linker compounds and Drug Linker Ligand conjugates are provided that have auristatins linked via the C-terminus. The conjugates show efficacy without the need for a self-immolative group to release the drug.Type: GrantFiled: March 18, 2009Date of Patent: December 17, 2013Assignee: Seattle Genetics, Inc.Inventors: Peter Senter, Svetlana Doronina, Timothy Bovee
-
Patent number: 8603483Abstract: The invention relates to conjugates of anti-integrin specific antibodies with cytotoxic compounds, the synthesis, selection, and use of such conjugates for use in cancer therapy or other diseases mediated by cell proliferation, cell migration, or inflammation and which pathology involves angiogenesis or neovascularization of new tissue. In addition the invention relates to combination therapy of such diseases wherein the treatment comprises use of said conjugates in combination with one or more other treatment modalities including but not limited to: chemotherapy, surgery or radiation therapy. The preferred conjugates contain maytansinoid compounds linked to the antibody by a disulfide linkage, and preferred chemotherapeutic agents are doxorubicin, a taxane, a camptothecin, a podophyllotoxin, a nucleoside analog, or a pyrimidine analog.Type: GrantFiled: November 30, 2005Date of Patent: December 10, 2013Assignees: Janssen Biotech, Inc., Immunogen, Inc.Inventors: Qiming Chen, Mohit Trikha, Robert J. Lutz, Rita M. Steeves, Godfrey Amphlett
-
Publication number: 20130323169Abstract: The present invention relates to linker molecules that readily conjugate cellular recognition ligand at one end and drug payload at the other, and are useful in treating or preventing cancer, an autoimmune disease, an inflammatory condition, a central nervous system disorder or an infection.Type: ApplicationFiled: May 31, 2013Publication date: December 5, 2013Inventors: Ze-Qi Xu, Qianli Wang, Augustine Rudolph Joseph, Zhiqiang Fang
-
Publication number: 20130324706Abstract: The present invention relates to method for connecting a protein and a drug to a protein drug conjugate, wherein the drug is linked to the protein through a specific branched linker, said branched linker comprises a peptide chain and is derived from o-hydroxy p-amino benzylic alcohol, wherein the peptide chain is connected to the phenyl ring via the p-amino group, the drug is connected to the phenyl ring via the benzylic alcohol moiety, and the protein is connected to the phenyl ring via the o-hydroxy group; further to a process for the preparation of said protein-drug-conjugates via various intermediates, to the pharmaceutical use of such protein drug conjugates, such as methods of controlling the growth of undesirable cells, to pharmaceutical compositions comprising such protein drug conjugates, and to intermediates of the preparation of the protein drug conjugates.Type: ApplicationFiled: February 23, 2012Publication date: December 5, 2013Inventors: Laurent Ducry, Bernhard Stump, Heilam Wong, Jin She, Gayle Phillips
-
Publication number: 20130323268Abstract: New ansamitocin derivatives bearing a linking group are disclosed. Also disclosed are methods for the synthesis of these new ansamitocin derivatives and methods for their linkage to cell-binding agents. The ansamitocin derivative-cell-binding agent conjugates are useful as therapeutic agents, which are delivered specifically to target cells and are cytotoxic. These conjugates display vastly improved therapeutic efficacy in animal tumor models compared to the previously described agents.Type: ApplicationFiled: November 3, 2011Publication date: December 5, 2013Applicant: IMMUNOGEN, INC.Inventors: Ravi V.J. Chari, Wayne C. Widdison, Sharon D. Wilhelm
-
Publication number: 20130323234Abstract: The present invention relates to a polypeptide comprising 7 ?-strands A, B, C, D, E, F, and G sequentially connected together by connecting chains of amino acids, and a first ?-helix sequentially located on the EF chain between ?-strands E and F, wherein the ?-strands are arranged so as to form a first ?-sheet comprising ?-strands A, B, D, and E, and a second ?-sheet comprising ?-strands C, F and G, said first and second ?-sheets being covalently bonded together so as to form a first Ig domain; wherein the EF chain between ?-strands E and F comprises the sequence X1-X2-X3-X4-K5H6 (SEQ ID NO:98), and X1, X3 and X4 are each independently any amino acid residue, characterized in that X2 is selected from the group consisting of A, G, I, V, L, R, S, T, Q, P, N, M, H, W, and pharmaceutically acceptable salts, stereoisomers, tautomers, solvates, and prodrugs thereofType: ApplicationFiled: January 7, 2013Publication date: December 5, 2013Applicant: COVX TECHNOLOGIES IRELAND LIMITEDInventor: Covx Technologies Ireland Limited
-
Patent number: 8598323Abstract: Described are Galectin-1/Ig fusion constructs and methods of use thereof, e.g., in diagnostic and biomedical assays, and as therapeutic agents for the treatment of conditions associated with immune dysfunction, e.g., autoimmune diseases, and cancers.Type: GrantFiled: June 22, 2010Date of Patent: December 3, 2013Assignee: The Brigham and Women's Hospital, Inc.Inventors: Charles J. Dimitroff, Filiberto Cedeno Laurent, Steven R. Barthel
-
Publication number: 20130317201Abstract: It is an object of the present invention to provide an anti-cadherin antibody having a high internalization capacity and provide an anti-cadherin antibody-drug conjugate that effectively kills cadherin-expressing cancer cells with the use of such antibody. The present invention provides an anti-cadherin antibody which recognizes a cadherin domain 1 (EC1) of cadherin and exhibits a high internalization capacity.Type: ApplicationFiled: October 28, 2011Publication date: November 28, 2013Applicant: PERSEUS PROTEOMICS INC.Inventors: Keisuke Ishii, Keiko Katsumi, Tadashi Matsuura, Yukio Sudo, Katsuyuki Mitomo, Katsushi Kouda
-
Publication number: 20130309257Abstract: In one aspect, there is provided a protein-drug conjugate compound comprising a protein covalently attached by a linker to one or more drug moieties, wherein the linker has a half-life of from 1 hour to 50 hours in phosphate buffered saline at 37° C. A carbonyl derivative of LU103793 is also described that can be used in a protein-drug conjugate compound comprising an antibody covalently attached by a linker to the drug moiety comprising, consisting or consisting essentially of the carbonyl derivative.Type: ApplicationFiled: March 25, 2013Publication date: November 21, 2013Applicant: Philogen S.P.A.Inventor: Casi Giulio
-
Publication number: 20130309256Abstract: The present invention provides Ligand-Drug Conjugates, Drug-Linkers, Linkers, and Ligand-Linker Conjugates comprising a self-stabilizing linker assembly component.Type: ApplicationFiled: March 13, 2013Publication date: November 21, 2013Inventor: Seattle Genetics, Inc.
-
Publication number: 20130302359Abstract: The invention relates to novel benzodiazepine derivatives with antiproliferative activity and more specifically to novel benzodiazepine compounds of formula (I)-(VII). The invention also provides conjugates of the benzodiazepine compounds linked to a cell-binding agent. The invention further provides compositions and methods useful for inhibiting abnormal cell growth or treating a proliferative disorder in a mammal using the compounds or conjugates of the invention.Type: ApplicationFiled: March 14, 2013Publication date: November 14, 2013Inventors: Wei Li, Michael Louis Miller, Nathan Elliott Fishkin, Ravi V.J. Chari
-
Publication number: 20130295104Abstract: Novel anti-cancer agents, including, but not limited to, antibodies and immunoconjugates, that bind to CD37 are provided. Methods of using the agents, antibodies, or immunoconjugates, such as methods of inhibiting tumor growth are further provided.Type: ApplicationFiled: March 12, 2013Publication date: November 7, 2013Inventors: Jutta DECKERT, Peter Park, Daniel Tavares, Lingyun Rui
-
Publication number: 20130295007Abstract: The invention provides anti-PMEL17 antibodies and immunoconjugates and methods of using the same.Type: ApplicationFiled: April 30, 2013Publication date: November 7, 2013Applicant: GENENTECH, INC.Inventors: Youjun Chen, William Mallet, Paul Polakis, Christine Tan, Jyoti Asundi, Suzanna Clark
-
Publication number: 20130281678Abstract: The invention provides a process for preparing a cell-binding agent chemically coupled to a drug. The process comprises covalently attaching a linker to a cell-binding agent, a purification step, conjugating a drug to the cell-binding agent and a subsequent purification step.Type: ApplicationFiled: February 25, 2013Publication date: October 24, 2013Inventors: Yong DAI, Yong WANG, Shengjin JIN, Deborah H. MESHULAM, Godfrey W. AMPHLETT
-
Publication number: 20130280281Abstract: The present invention relates to short polypeptides (e.g., fewer than 19 amino acids in length) and longer polypeptides (e.g., 19 or more amino acids in length) having one or more D-amino acids as targeting moieties. These polypeptides, when conjugated to agents (e.g., therapeutic agents or transport vectors) are capable of transporting the agents across the BBB or into particular cell types. In particular, the short polypeptides can include one or more D-amino acids. These compounds are therefore particularly useful in the treatment of neurological diseases or diseases associated with particular cell types, organs, or tissues.Type: ApplicationFiled: July 4, 2011Publication date: October 24, 2013Inventors: Jean-Paul Castaigne, Michel Demeule, Christian Che, Carine Thiot, Laurence Peslherbe